Today, non-small cell lung cancer patients with an EML4-ALK fusion are routinely treated with ALK inhibitors as first-line chemotherapy8, 9, even though this fusion was first reported only eight years ago. The gene discussed is EML4; the disease is non-small cell lung carcinoma.